Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2017 March;61(1) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2017 March;61(1):33-47

CURRENT ISSUE
 

ARTICLE TOOLS

Publication history
Reprints
Cite this article as

THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

A Journal on Nuclear Medicine and Molecular Imaging


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,481


eTOC

 

REVIEW  PRECLINICAL IMAGINGFREEfree


The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2017 March;61(1):33-47

DOI: 10.23736/S1824-4785.16.02949-6

Copyright © 2016 EDIZIONI MINERVA MEDICA

language: English

Preclinical imaging in oncology: advances and perspectives

Francesca IOMMELLI 1, Viviana DE ROSA 1, Cristina TERLIZZI 2, Silvana DEL VECCHIO 2

1 Institute of Biostructures and Bioimaging, National Research Council, Naples, Italy; 2 Department of Advanced Biomedical Sciences, Federico II University, Naples, Italy


PDF  


Preclinical imaging with radiolabeled probes became an integral part of the complex translational process that moves a newly developed compound from laboratory to clinical application. Imaging studies in animal tumor models may be undertaken to test a newly synthesized tracer, a newly developed drug or to interrogate, in the living organism, specific molecular and biological processes underlying tumor growth and progression. The aim of the present review is to outline the current knowledge and future perspectives of preclinical imaging in oncology by providing examples from recent literature. Among the biological processes and molecular targets that can be visualized with radiolabeled probes in animal tumor models, we focused on proliferation, expression of targets suitable for therapy, glycolytic phenotype, metastatic dissemination, tumor angiogenesis and survival. The major contribution of preclinical imaging emerging from these studies is the development and validation of imaging biomarkers that can be translated into the clinical context for patient selection and evaluation of tumor response to molecularly targeted agents.


KEY WORDS: Molecular imaging - Positron-emission tomography - Single-photon emission-computed tomography - Animal models

top of page

Publication History

Issue published online: January 5, 2017
Article first published online: November 18, 2016

Cite this article as

Iommelli F, De Rosa V, Terlizzi C, Del Vecchio S. Preclinical imaging in oncology: advances and perspectives. Q J Nucl Med Mol Imaging 2017;61:33-47. DOI: 10.23736/S1824-4785.16.02949-6

Corresponding author e-mail

delvecc@unina.it